Home » Newsletters » BioWorld Science

BioWorld Science

May 18, 2015

View Archived Issues

Astellas Pharma presents milestones of fourth quarter of fiscal 2014

Sun Biomedical agrees to acquire Dimerix Bioscience

Eisai patents FGFR-4 inhibitors

Angion Biomedica plans phase III trial of BB3 in delayed kidney graft function

Tonix Pharmaceuticals starts phase III trial of TNX-102 SL for fibromyalgia

Dicerna expands phase I trial of DCR-MYC to include PNET cohort

Discovery Labs' phase IIa study of Aerosurf meets key objectives

Luye Pharma completes three studies for risperidone extended-release microspheres

FDA grants fast track designation to TRC-105 for renal cell carcinoma

Xadago launched in Germany for mid- to late-stage Parkinson's disease

ISIS-664844 selectively targets the P23H variant of Rhodopsin

Vaccination with FSPs shows potential for the treatment of MSI-H CRC

FDA approves Treximet for use in pediatric migraine

Novartis reports development of complement factor B inhibitors

FORUM Pharmaceuticals patents nAChR alpha7 agonists

Chugai discloses DDR1 inhibitors

Taisho develops antibacterial hydroxamic acids

Boehringer Ingelheim exercises option for Pharmaxis drug candidate

Preliminary phase I trial results presented on DC vaccination therapy for AML

Selecta and Genethon to investigate technology enabling repeat dosing of gene therapies

Alnylam files for permission to start phase I/II trial of alpha1-antitrypsin RNAi therapeutic

Mitsubishi Tanabe files application in Japan for Remicade in Kawasaki disease

Sacituzumab govitecan awarded FDA fast track designation for NSCLC

Bristol-Myers Squibb's IPN-007 receives U.S. orphan status for progressive supranuclear palsy

Prostanoid EP2/3 agonist ONO-8055: a promising agent for underactive bladder

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...